BTLA Screening Services

B and T Lymphocyte Attenuator, or BTLA, is a human protein which inhibits T cell activation. BTLA is expressed by cytotoxic T cells (CTL), which are T lymphocytes that are able to kill foreign pathogens, viral-infected cells, and cancer cells. BTLA binding to its ligand, herpesvirus entry mediator (HVEM), results in inhibition of CTL activation. Certain cancers are able to evade the immune system by taking advantage of this inhibitory pathway.  

In the field of immuno oncology, inhibition of the HVEM:BTLA pathway is being investigated as a way to increase the immune system’s response to cancer. These services can provide a first-line screen before further screening is done to determine the functional output, agonistic or antagonistic, of this perturbation.

  • Screen for inhibitors/targets using our BTLA:HVEM assay
  • Select from IC50 determination and single point concentrations
  • Receive data within days of compound submission
  • Perform follow-up studies using the same soluble receptors manufactured in-house
  • Get questions answered or project guidance in a time-efficient manner

BPS Bioscience also offers several recombinant proteins related to this pathway;

 In addition BPS offers the BTLA: HVEM Inhibitor Screening Assay Kit. The chemiluminescent assay kit measures the levels of BTLA binding to HVEM. This kit can be utilized to screen for and profile inhibitors of BTLA: HVEM signaling.

Contact BPS today to find out more about how we can assist you in your BTLA-related research.

Assay Format:

Note: Image not drawn to scale. 

Not quite what you're looking for? We also offer custom assays for several other immunotherapy targets. Our Custom Assay Development Services allow for flexibility to meet your specific research needs

B and T Lymphocyte Attenuator, or BTLA, is a human protein which inhibits T cell activation. BTLA is expressed by cytotoxic T cells (CTL), which are T lymphocytes that are able to kill foreign pathogens, viral-infected cells, and cancer cells. BTLA binding to its ligand, herpesvirus entry mediator (HVEM), results in inhibition of CTL activation. Certain cancers are able to evade the immune system by taking advantage of this inhibitory pathway.